We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




AI Platform Identifies 99% of Positive Cancer Cases in Pathology Reports

By LabMedica International staff writers
Posted on 14 Mar 2022

For most people, the shock of a cancer diagnosis quickly gives way to an action plan — disease research, doctor appointments, treatment options, and support outlets. More...

But many patients are not able to take these steps or advocate for themselves. Some simply don't know how to move forward, which results in more complicated and expensive care, reduced life expectancies, and inferior health outcomes. A new artificial intelligence (AI) platform disrupts the manual and repetitive processes in healthcare to identify positive cancer diagnosis and incidental findings in real time, classify those diagnoses by primary site, and route those patients to cancer navigators and other staff to immediately start the cancer care journey.

The results of this new platform from Azra AI (Franklin, TN, USA) include faster time to treatment, increased navigator time with patients, and better patient retention in a health system's oncology program. In addition, Azra AI's platform improves healthcare operations with dramatic operational and financial gains through automation. More specifically, this new technology decreased time from diagnosis-to-treatment by seven days across all cancer types, improved patient retention by 75% and increased revenues over 10% in the first 14 months of use.

Azra AI's technology is making a tremendous impact in the oncology realm and has saved countless hours for hospital staff by combing through CT scan results with exceptional speed and accuracy. Healthcare leaders have also found that the Azra AI platform performs better than manual processes and completes reviews much faster. A recent analysis of one health system's records using the Azra AI platform found that the technology identified 99% of positive cancer cases in pathology reports that had previously been manually reviewed by healthcare staff.

"We are already helping thousands of cancer patients and clinicians everyday with our AI-enhanced intelligent workflows," said Azra AI CEO Chris Cashwell. "With the crisis in nurse staffing and uncertainty of post-COVID cancer patient volumes, our technology can be a lifeline to clinicians and a life saver for patients. From finding incidental lung nodules to reducing time to treatment, providers are having a profound impact using our technology."

Related Links:
Azra AI 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Automated Immunoassay Analyzer
SuperFlex™
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.